Find clinical trials for Lung Cancer in Chicago, IL

combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:* E...

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as...

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV).Some cancers shed DNA (circulating tum...

HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently ...

N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study ...

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study...